Claybrook Capital’s Pfizer PFE Stock Holding History

Claybrook Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$355K	Buy	10,705 +205	+2%	+$7.25K	0.2%	103
2023 Q2	$385K	Hold	10,500	–	–	0.21%	100
2023 Q1	$428K	Hold	10,500	–	–	0.24%	93
2022 Q4	$538K	Sell	10,500 -4,135	-28%	-$198K	0.33%	74
2022 Q3	$640K	Hold	14,635	–	–	0.41%	71
2022 Q2	$767K	Sell	14,635 -50	-0.3%	-$2.55K	0.45%	66
2022 Q1	$760K	Sell	14,685 -75	-0.5%	-$3.89K	0.38%	73
2021 Q4	$872K	Buy	14,760 +75	+0.5%	+$3.72K	0.41%	69
2021 Q3	$632K	Sell	14,685 -83,961	-85%	-$3.72M	0.32%	81
2021 Q2	$3.86M	Buy	98,646 +52,961	+116%	+$2.06M	1.26%	21
2021 Q1	$1.66M	Hold	45,685	–	–	0.96%	36
2020 Q4	$1.68M	Sell	45,685 -2,414	-5%	-$88.5K	1.11%	35
2020 Q3	$1.68M	Buy	48,099 +1,581	+3%	+$55.4K	1.26%	26
2020 Q2	$1.44M	Buy	+46,518	New	+$1.58M	1.24%	25
2019 Q1	–	Sell	-3,995	Closed	-$165K	–	514
2018 Q4	$165K	Sell	3,995 -339	-8%	-$14.1K	0.05%	150
2018 Q3	$181K	Hold	4,334	–	–	0.11%	80
2018 Q2	$149K	Hold	4,334	–	–	0.09%	80
2018 Q1	$146K	Sell	4,334 -899	-17%	-$30.9K	0.1%	80
2017 Q4	$180K	Buy	+5,233	New	+$178K	0.13%	85

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Claybrook Capital's PFE Position: Q3 2023 in Review

Claybrook Capital increased its Pfizer (PFE) stake by 2% in Q3 2023, buying an estimated $7.25K and bringing the position to 10,705 shares worth $355K. The position accounts for 0.2% of the portfolio, ranked #103.

Claybrook Capital first reported a position in PFE in Q4 2017 and has held it in 19 quarters since. The position peaked at $3.86M in Q2 2021. 2,926 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

Claybrook Capital held 10,705 shares of Pfizer worth $355K as of Q3 2023.
Claybrook Capital bought 205 Pfizer shares in Q3 2023, an estimated $7.25K.
Pfizer made up 0.2% of Claybrook Capital's portfolio in Q3 2023, its #103 holding.
Claybrook Capital first reported a position in Pfizer in Q4 2017 and has held it in 19 quarters since.
Claybrook Capital's Pfizer position peaked at $3.86M in Q2 2021.
2,926 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Claybrook Capital's 13F filing for Q3 2023, filed 24 Oct 2023.